

## FORM 4

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL

OMB Number: 3235-0287  
 Estimated average burden  
 hours per response: 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

|  |  |  |  |  |  |  |  |  |
|--|--|--|--|--|--|--|--|--|
| 1. Name and Address of Reporting Person*<br><u>Casdin Partners Master Fund, L.P.</u> |  |  | 2. Issuer Name and Ticker or Trading Symbol<br><u>STANDARD BIOTOOLS INC. [ LAB ]</u> |  |  | 5. Relationship of Reporting Person(s) to Issuer<br>(Check all applicable)   |  |  |
| (Last) (First) (Middle)<br><b>1350 AVENUE OF THE AMERICAS</b><br><b>SUITE 2600</b>   |  |  | 3. Date of Earliest Transaction (Month/Day/Year)<br><b>02/28/2025</b>                |  |  | <input checked="" type="checkbox"/> Director <input checked="" type="checkbox"/> 10% Owner<br><input type="checkbox"/> Officer (give title below) <input type="checkbox"/> Other (specify below)               |  |  |
| (Street)<br><b>NEW YORK NY 10019</b>   |  |  | 4. If Amendment, Date of Original Filed (Month/Day/Year)                             |  |  | 6. Individual or Joint/Group Filing (Check Applicable Line)<br><input type="checkbox"/> Form filed by One Reporting Person<br><input checked="" type="checkbox"/> Form filed by More than One Reporting Person |  |  |
| (City) (State) (Zip)   |  |  |  |  |  |  |  |  |

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

| 1. Title of Security (Instr. 3) | 2. Transaction Date (Month/Day/Year) | 2A. Deemed Execution Date, if any (Month/Day/Year) | 3. Transaction Code (Instr. 8) | 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) |   |                       | 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) | 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 7. Nature of Indirect Beneficial Ownership (Instr. 4) |
|---------------------------------|--------------------------------------|--|--------------------------------|---|---|-----------------------|---|--|---|
|                                 |                                      |  |                                | Code  | V | Amount                |   |  |   |
| Common Stock                    | 02/28/2025                           |  | P                              |   |   | 4,820,959             | A   | \$1.065  | 58,846,780  |
| Common Stock                    | 02/28/2025                           |  | J <sup>(2)</sup>               |   |   | 545,000               | A   | \$1.065  | 59,391,780  |
| Common Stock                    | 02/28/2025                           |  | J <sup>(2)</sup>               |   |   | 545,000               | D   | \$1.065  | 0   |
| Common Stock                    | 02/28/2025                           |  | A                              |   |   | 58,215 <sup>(4)</sup> | A   | \$1.065 <sup>(5)</sup>                                   | 2,806,470 <sup>(6)</sup>                              |
| Common Stock                    |                                      |  |                                |   |   |                       |   |  | 13,939,637  |
| Common Stock                    |                                      |  |                                |   |   |                       |   |  | 2,744,219   |

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned  
(e.g., puts, calls, warrants, options, convertible securities)

| 1. Title of Derivative Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Transaction Date (Month/Day/Year) | 3A. Deemed Execution Date, if any (Month/Day/Year) | 4. Transaction Code (Instr. 8) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) | 6. Date Exercisable and Expiration Date (Month/Day/Year) |     | 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) | 8. Price of Derivative Security (Instr. 5) | 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) | 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 11. Nature of Indirect Beneficial Ownership (Instr. 4) |
|--|--|--------------------------------------|--|--------------------------------|--|--|-----|---|--|--|---|--|
|  |  |                                      |  |                                |  | Code   | V   |   |  |  |   |  |
|  |  |                                      |  |                                |  | (A)  | (D) | Date Exercisable  | Expiration Date                            | Title  | Amount or Number of Shares                                |  |
|  |  |                                      |  |                                |  |  |     |   |  |  |   |  |

1. Name and Address of Reporting Person\*

Casdin Partners Master Fund, L.P.

(Last) (First) (Middle)

**1350 AVENUE OF THE AMERICAS****SUITE 2600**

(Street)

**NEW YORK NY 10019**

(City) (State) (Zip)

1. Name and Address of Reporting Person\*

Casdin Eli

(Last) (First) (Middle)

1350 AVENUE OF THE AMERICAS  
SUITE 2600

(Street)  
NEW YORK NY 10019

(City) (State) (Zip)

1. Name and Address of Reporting Person\*

Casdin Capital, LLC

(Last) (First) (Middle)

1350 AVENUE OF THE AMERICAS  
SUITE 2600

(Street)  
NEW YORK NY 10019

(City) (State) (Zip)

1. Name and Address of Reporting Person\*

Casdin Partners GP, LLC

(Last) (First) (Middle)

1350 AVENUE OF THE AMERICAS  
SUITE 2600

(Street)  
NEW YORK NY 10019

(City) (State) (Zip)

1. Name and Address of Reporting Person\*

Casdin Private Growth Equity Fund II, L.P.

(Last) (First) (Middle)

1350 AVENUE OF THE AMERICAS  
SUITE 2600

(Street)  
NEW YORK NY 10019

(City) (State) (Zip)

1. Name and Address of Reporting Person\*

Casdin Private Growth Equity Fund II GP, LLC

(Last) (First) (Middle)

1350 AVENUE OF THE AMERICAS, SUITE 2600

(Street)  
NEW YORK NY 10019

(City) (State) (Zip)

1. Name and Address of Reporting Person\*

Casdin Private Growth Equity Fund, L.P.

(Last) (First) (Middle)

1350 AVENUE OF THE AMERICAS  
SUITE 2600

(Street)  
NEW YORK NY 10019

(City) (State) (Zip)

1. Name and Address of Reporting Person\*

Casdin Amplify Fund, LP

(Last) (First) (Middle)

1350 AVENUE OF THE AMERICAS  
SUITE 2600

(Street)  
NEW YORK NY 10019

(City) (State) (Zip)

1. Name and Address of Reporting Person\*

CASDIN PRIVATE GROWTH EQUITY FUND GP, LLC

(Last) (First) (Middle)

1350 AVENUE OF THE AMERICAS  
SUITE 2600

(Street)  
NEW YORK NY 10019

(City) (State) (Zip)

**Explanation of Responses:**

1. The securities are owned directly by Casdin Partners Master Fund, L.P. (the "Master Fund") and may be deemed to be indirectly beneficially owned by (i) Casdin Capital, LLC ("Casdin"), the investment adviser to the Master Fund, (ii) Casdin Partners GP, LLC (the "GP"), the general partner of the Master Fund, and (iii) Eli Casdin, the managing member of Casdin and the GP.
2. Represents a cross-trade, pursuant to which Casdin Amplify Fund, LP ("Amplify") transferred 545,000 shares of Common Stock to the Master Fund.
3. The securities were owned directly by Amplify and were deemed to be indirectly beneficially owned by (i) Casdin, the investment adviser to Amplify, (ii) the GP, the general partner of Amplify, and (iii) Eli Casdin, the managing member of Casdin Capital, LLC and Casdin Partners GP, LLC.
4. Represents Restricted Stock Units ("RSUs") that vest as to 25% on the last day of the last month of each fiscal quarter of 2025, subject to the Reporting Person's continued service through the applicable vesting date.
5. The RSUs were issued to the Reporting Person, who elected to take RSUs in lieu of \$62,000 in cash compensation for services as a board member.
6. Includes RSUs.
7. The securities are owned directly by Eli Casdin.
8. The securities are owned directly by Casdin Private Growth Equity Fund II, L.P. (the "Equity Fund II") and may be deemed to be indirectly beneficially owned by (i) Casdin, the investment adviser to the Equity Fund II, and (ii) Eli Casdin, the managing member of Casdin.
9. The securities are owned directly by Casdin Private Growth Equity Fund, L.P. (the "Equity Fund") and may be deemed to be indirectly beneficially owned by (i) Casdin, the investment adviser to the Equity Fund, and (ii) Eli Casdin, the managing member of Casdin.

**Remarks:**

Eli Casdin has been deputized to represent the Reporting Persons on the board of directors of the Issuer. By virtue of Mr. Casdin's representation, for purposes of Section 16 of the Securities Exchange Act of 1934 (the "Exchange Act"), each of the Reporting Persons may be deemed directors by deputation of the Issuer. Each Reporting Person disclaims beneficial ownership in the securities reported on this Form 4 except to the extent of its pecuniary interest, if any, therein, and this report shall not be deemed to be an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose.

Casdin Partners Master Fund, LP, By: Casdin Partners GP, LLC, its General Partner, By: 03/04/2025  
/s/ Eli Casdin, Managing Member  
/s/ Eli Casdin, Eli Casdin 03/04/2025  
Casdin Capital LLC, By: /s/ Eli Casdin, Managing Member 03/04/2025  
Casdin Partners GP LLC, By: /s/ Eli Casdin, Managing Member 03/04/2025  
Casdin Private Growth Equity Fund II, L.P., By: Casdin Private Growth Equity Fund II GP, LLC, its General Partner, By: /s/ Eli Casdin, Managing Member 03/04/2025  
Casdin Private Growth Equity Fund GP II, LLC, By: /s/ Eli Casdin, Managing Member 03/04/2025  
Casdin Private Growth Equity Fund, L.P., By: Casdin Private Growth Equity Fund II GP, LLC, its General Partner, By: /s/ Eli Casdin, Managing Member 03/04/2025  
Casdin Amplify Fund, LP, By: Casdin Partners GP, LLC, its General Partner, By: /s/ Eli Casdin, Managing Member 03/04/2025

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**